Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - Alnylam is recognized as a leading RNAi company, leveraging Nobel Prize-winning science to develop innovative therapies [2] - The company has successfully launched 6 marketed products and has a robust clinical pipeline with over 20 programs [2] - Alnylam is focused on three main areas for future growth, with an emphasis on achieving leadership in TTR (transthyretin) therapeutics [3] Company Overview - Alnylam has built an extraordinary company over the last couple of decades, emphasizing innovation and the development of new medicines [2] - The company is committed to maintaining a productive innovation engine that will continue to deliver new therapies for decades [2] Product Launch - The launch of AMVUTTRA for cardiomyopathy has been described as a terrific start, indicating strong initial market reception [3]